Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.
about
sameAs
Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in IndiaIncidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.Gender-specific considerations in the antiretroviral management of HIV-infected women.Evaluation of a sex-based difference in the pharmacokinetics of digoxin.Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine.Adverse effects of highly active antiretroviral therapy in developing countries.Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors.A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitationHLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients.Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study.Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999.Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions.Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (
P2860
Q28540682-14EF60F9-44A9-4360-9D12-E41BC5CCF57EQ35146943-2AB81394-63CF-4830-92D7-BB8872F006A9Q35552675-11C7D64B-60A3-4098-9F0C-4731BA92C3F8Q36074119-B747DE85-7AE2-41E8-BEDF-8ADC4836DA59Q36140662-763A5653-A91C-4463-8799-959DDFED0A5BQ36410175-28343AED-6042-43A4-8085-CAFED92F7B7DQ36621432-9ED876AC-D6D2-404A-AFAD-C388F31959FEQ36945761-89E70C3F-DA5F-4E1F-92F5-E7B8CB357612Q36954711-CAC26412-3477-4D5F-81C2-446029B78E6AQ37271902-BCD7FFC8-74D8-4D68-BDBD-21B1897CF663Q37414313-9F6AC24D-2570-4056-8946-894DD2897A37Q39553824-77AA12F7-6356-4F74-820A-9BFAF93D4DC2Q43282851-ED77EBA4-93A9-41EB-82F4-E8E3B0FFC8F7Q43851688-DDD3D71E-3FE3-49F1-B472-014360EB1DB5Q44183256-796C34C4-EB9E-4AB4-8200-6B2C39EECFBFQ44200937-7D73705F-2A4C-4DB6-9032-D10F363B0BFAQ46102935-C7BA1FC9-CA7A-41BB-B7FD-27705934F406Q50685772-93400D14-1D15-4976-B06E-BBE387F43628Q51202282-A2B8AC1A-3E6C-40AF-BDF5-521A136F3F3BQ58960855-910F29EE-87F8-4562-8E07-3A3C4BA0A505
P2860
Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Female sex and the use of anti ...... iated with nevirapine therapy.
@en
Female sex and the use of anti ...... iated with nevirapine therapy.
@nl
type
label
Female sex and the use of anti ...... iated with nevirapine therapy.
@en
Female sex and the use of anti ...... iated with nevirapine therapy.
@nl
altLabel
Female sex and the use of anti ...... ciated with nevirapine therapy
@en
Female sex and the use of anti ...... ciated with nevirapine therapy
@nl
prefLabel
Female sex and the use of anti ...... iated with nevirapine therapy.
@en
Female sex and the use of anti ...... iated with nevirapine therapy.
@nl
P2093
P50
P1433
P1476
Female sex and the use of anti ...... ciated with nevirapine therapy
@en
Female sex and the use of anti ...... iated with nevirapine therapy.
@en
P2093
Ammassari A
Annalisa Barracchini
Antinori A
Barracchini A
Cingolani A
De Longis P
Francesco Baldini
Maria Gabriella Rizzo
P304
P356
10.1097/00002030-200108170-00018
P407
P50
P577
2001-08-01T00:00:00Z